24 results
8-K
EX-99.1
MIRM
Mirum Pharmaceuticals Inc
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
) after an aluminum-based antacid.
PREGNANCY
No studies in pregnant women or animal reproduction studies have been conducted with CHOLBAM. Women who
8-K
EX-99.1
MIRM
Mirum Pharmaceuticals Inc
9 Nov 22
Results of Operations and Financial Condition
7:30am
including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women
8-K
EX-99.1
MIRM
Mirum Pharmaceuticals Inc
24 Oct 22
Regulation FD Disclosure
8:46am
clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary
8-K
EX-99.1
MIRM
Mirum Pharmaceuticals Inc
4 Aug 22
Results of Operations and Financial Condition
4:03pm
clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis
8-K
EX-99.1
MIRM
Mirum Pharmaceuticals Inc
6 Jun 22
Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors
8:32am
, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults
8-K
EX-99.1
o2k 1xkim8
5 May 22
Results of Operations and Financial Condition
8:05am
8-K
EX-99.1
rp5dmonafiyayq
9 Mar 22
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
4:05pm
8-K
EX-99.1
8gc7ogr
11 Jan 22
Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones
9:00am
8-K
EX-99.1
c9b 7hh3t
15 Nov 21
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
4:06pm
8-K
EX-99.1
htmhi5g
29 Sep 21
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
4:42pm
8-K
EX-99.1
lvtsuoh5 iuo2q487k
5 Aug 21
Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
4:36pm
10-K
7k89qs8b4dw86m
12 Mar 20
Annual report
4:16pm
424B4
894n01jt8
9 Jan 20
Prospectus supplement with pricing info
5:11pm
DRS
nnjzru
27 Dec 19
Draft registration statement
12:00am
424B4
19ohxhydq o6
18 Jul 19
Prospectus supplement with pricing info
4:04pm